RSV A Memphis 37
PreclinicalBiologic
RSV A Memphis 37 is one of 71 biologic programs targeting Respiratory Syncytial Virus Infection. It is currently in Preclinical.
3
Indications
4
Total Trials
1
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
127 competitors in Adult
#DrugCompanyPhaseTrials
1Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Mounjaro
Eli LillyPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Myqorzo
CCytokinetics
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 2
Skyclarys
BiogenPhase 1
Sunlenca
GileadPhase 1
NM8074
NNovelMed Therapeutics
Phase 2
EB-1020
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Respiratory Syncytial Virus Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RSV A Memphis 37. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- IImperial College London